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Abstract
Despite growing skepticism regarding the efficacy of antidepressants, global con-
sumption is increasing at an unprecedented path with unknown implications for so-
ciety. We estimate the causal effect of this increase on mental health outcomes using
an IV strategy that exploits detailed drug sales data from Switzerland between 2002
and 2014. Our instrument, a modified version of the popular shift-share instrument,
relies on the national growth in antidepressant sales for pharmaceutical companies
(the shift) - mainly due to product innovation - and assigns it locally using regional
non-antidepressant market shares. Our estimates show that an increase in antide-
pressants sales does not significantly affect suicide rates but cause an increase of
hospital admissions for mental disorder and for depression. The causal effects prove
to be resistant to several robustness checks.
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1. Introduction
Antidepressants are among the most widely prescribed drugs. Their consumption has
been growing at a steady pace and has doubled over the last decade (McCarthy, 2013).
Despite this substantial increase in antidepressant use, prescription guidelines have not
been substantially altered in recent years (Anderson et al., 2000, 2008), while studies sug-
gests that prescription thresholds have been lowered and antidepressants are increasingly
prescribed off-label (Moore et al., 2009). Consequently, there is rising concern over the
efficacy of these drugs and the potential implications for society. Although evidence on
efficacy is mostly grounded on randomized controlled trials (RCT), several meta-studies
have questioned the results (Jakobsen et al., 2017; Cipriani et al., 2016; Kirsch et al.,
2008; Healy and Whitaker, 2003). Critics point to methodological issues, such as the
short duration of the RCT, small sample size, under-reporting of adverse events during
the trials, blind-breaking and the use of a placebo washout period. This study intends to
contribute to the ongoing debate on antidepressant efficacy with a causal estimate of the
effect of antidepressant drug sales on several mental health outcomes.
Several recent meta-studies shed light on the efficacy of antidepressant treatment and
the occurrence of adverse events. Awareness for adverse events was spurred in October
2004 when the US Food and Drug Administration (FDA) issued a black box warning for
all antidepressants (Busch et al., 2014). This announcement motivated several authors
to analyze the drug trial data submitted to the FDA to obtain US market access. The
results of these (and other) studies suggest that baseline depression severity matters for
antidepressant efficacy, while clinical efficacy is only significant for the most severely
depressed, and benefits are minimal or non-existent in patients with mild or moderate
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symptoms of depression (Fournier et al., 2010; Stone et al., 2009; Kirsch et al., 2008).
Antidepressants appear to have particularly adverse effects for children, adolescents and
the elderly. Indeed, their use is associated with a modest increase in suicide risk among
pediatric patients, and with several adverse health outcomes among the elderly (Cipriani
et al., 2016; Coupland et al., 2011; Stone et al., 2009; Hammad et al., 2006).
According to the 2008 British Association for Psychopharmacology guidelines, antide-
pressant treatment is recommended only in moderate and severe cases of depression, and
possibly in combination with some form of psychotherapy (Anderson et al., 2008).1 Evi-
dence suggests that the prescription threshold shifted towards milder forms of depression,
thanks to the introduction of Selective Serotonin Reuptake Inhibitors (SSRI) (Moore
et al., 2009). At the time of their introduction in the ’90s, SSRI were hailed as having
a comparative advantage over old classes of antidepressants , such as Tricyclic antide-
pressants (TCA), especially in terms of lower side-effects (Lane et al., 1995). Whether
this was because TCA were particularly harmful or because SSRI were indeed very safe,
has not been established in the literature yet (Cohen et al., 2000; Sharma et al., 2016;
Jakobsen et al., 2017).
There is an extensive medical literature on the spatial correlation between antidepressant
consumption and suicides with often mixed results (e.g., Gibbons et al., 2005). As far as
we know, the only paper that provides evidence of a negative causal relationship between
antidepressant consumption and suicides is Ludwig et al. (2009). Using data from 1980
to 2000, the authors exploit the differential introduction of SSRI drugs across countries
and find that an increase of SSRI sales by one pill per capita reduces suicides by 5%.
1 The most recent guidelines from the same association are from 2015 and, therefore, are not relevant
for the period under study. Nonetheless, these guidelines (Cleare et al., 2015) provide the same
recommendations.
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Although insightful, this result is no longer applicable to the current level of antidepressant
consumption because, nowadays, the large part of antidepressants consumed are SSRI,
and the marginal patient treated with antidepressant drugs likely suffers from a milder
form of depression as compared to the marginal patient at the beginning of the ’80s when
SSRI were introduced. Note also that antidepressant consumption in the US has increased
by 400% between the early nineties and the beginning of this century (Pratt et al., 2011),
and similar trends are observed in most other developed countries.
This paper provides new insights into the consequences of the surge in antidepressant
consumption. To achieve this aim, we exploit small area variations in antidepressant con-
sumption using sales data for Switzerland from 2002 to 2014. As illustrated by the maps
in Figure 1, antidepressant consumption shows considerable variation over both time and
space. We intend to exploit this variation to establish a causal link between antidepres-
sant sales and mental health outcomes. Our study contributes to the understanding of
the efficacy of antidepressant use in two main ways. The first contribution of this paper
lies in the investigation of health outcomes, such as hospitalization for mental health con-
ditions and depression, in addition to suicides that are usually characterized by a very-low
event probability. Ideally, we would also like to assess the effect of antidepressant use on
depression prevalence, but unfortunately, a reliable measure of depression prevalence is
not available for Switzerland.
The second contribution of this paper relates to the empirical strategy used to enhance
the causal interpretation of our results. We address the endogeneity concern that arises
in ecological studies by utilizing an instrumental variable (IV) approach. Our instrument
is inspired by the popular shift-share approach (Bartik, 1991) but substantially diverges
regarding its implementation. Similar to the standard shift-share instrument, it is es-
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sentially a weighted average of national manufacturer (pharmaceutical company) growth
rates (the shifts), but the weights of our instrumental variable depend on the manufacturer
market shares for non-antidepressant drugs in the base year (the shares). The variation
in the shares comes from historically grown differences in market power between manu-
facturers in different Swiss regions, while the change in the growth rates (net of year fixed
effects) mainly derives from the introduction of new products in the market (as reported
in Figure 2). The nature of the instrument allows us to alleviate concerns regarding the
correlation between the initial shares and health conditions of the region because we ex-
ploit the plausibly exogenous variation in the market power of pharmaceutical companies
in the non-antidepressant market.
Using a two-stage least squares fixed effects model, we find that antidepressant consump-
tion does not affect suicides. However, an increase in consumption of one defined daily
dose per 1,000 inhabitants (roughly 3% of 2003 sales) increases hospital admissions for
mental disorders by 2% and hospitalization for depression by more than 7%. These results
prove to be robust to the enlargement of the time gap between the base year (in which we
calculate the shares) and the years for which we estimate the effect. Moreover, in a series
of placebo estimates aimed to test the exogeneity of our instrument indirectly, we do not
find any evidence of relevant correlations between the increase in antidepressant sales in-
duced by our instrument and hospital admissions for diseases that should not be affected
by the increase in antidepressant use. The only exception is cancer, but the correlation
is negative (meaning fewer hospitalizations for cancer) and disappears as we increase the
time lag between the base year and the years for which we estimate the effect.
The remainder of this paper is organized as follows. In the next section, we introduce the
Swiss institutional setting in which we conduct our analysis. In Section 3, we describe the
5
data used for the analysis and the data aggregation process. In Section 4, we discuss our
empirical strategy while in Section 5 we present our results. Finally, Section 6 concludes.
2. Institutional setting
We use data for Switzerland to study the effects of antidepressant use on mental health
outcomes. Switzerland is a confederation of 26 cantons with considerable autonomy in
the organization and the provision of health care services. The supply of mental health
care is a cantonal responsibility, though the federal state organizes some of the funda-
mental financial aspects (Biller-Andorno and Zeltner, 2015). Private health insurance is
mandatory and regulated by federal laws. The insurance plan covers an extensive list
of prescription drugs and, therefore, Swiss consumers face almost no costs when using
antidepressants. A consumer can opt for a Health Maintenance Organization (HMO)
type of health insurance or a general practitioner (GP) scheme, which allows the con-
sumer to reduce the insurance premium. Cantonal authorities provide subsidies for those
consumers facing financial hardship. The minimum annual deductible amounts to 300
CHF (1 CHF ≈ 1 US $), but the consumer can choose a higher deductible, up to 2,500
CHF, against a decrease in the insurance premium. After the deductible is exhausted,
the consumer contributes by 10% to all health care expenses, up to a stop-loss amount
of 700 CHF. Moreover, the federal government introduced a 20% co-insurance rate for
off-patent brand name medications in 2006.
Individuals who suffer from mental disorders generally opt for the minimum deductible.
Moreover, the deductible is quickly exhausted by physician visits and psychotherapy con-
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sultations.2 To provide an idea of the potential costs of antidepressant treatment for a
patient, the price per defined daily dose for the most prescribed (brand name) drug in
Switzerland (Cipralex 10mg) is about 1.32 CHF, or 480 CHF a year. According to the
drug list, this drug has a 20% co-insurance rate. Therefore, a patient treated with this
drug pays at most 336 CHF a year out of pocket. No antidepressant is available ”over
the counter” since all antidepressants without exception are prescription drugs. Lastly,
Masiero et al. (2018) find that antidepressant consumption in Switzerland is associated
with physician density, suggesting that supplies may induce demand at least to some ex-
tent. All in all, consumers determine the demand for antidepressant drugs only to a small
degree.
The Federal Office of Public Health (FOPH) sets prices for prescription drugs in Switzer-
land. After a drug has been granted access to the Swiss market by the federal authority
(Swissmedic), the FOPH decides whether to include the drug in the list for reimbursement
(Spezialita¨tenlist - SL) upon evaluating its efficacy. Antidepressants are relatively expen-
sive in Switzerland, and the price difference between brand names and generic drugs is
not very large. Generic drugs are at least 50% more costly than in other European coun-
tries.3 These market characteristics suggest that drug manufacturers in Switzerland are
likely to compete on quantity rather than in prices. Since only physicians can prescribe
antidepressants and federal laws prohibit direct-to-consumer advertising for prescription
drugs, manufacturers can only influence their sales through physician detailing.
2 According to the Swiss tariff system for out-patient medical services (TARMED), the cost for a psychi-
atric consultation amounts to 11.20 CHF per five minutes. A psychotherapeutic consultation or a GP
consultation amount to 10.42 CHF per five minutes. For instance, with only two hours of treatment
per month, the deductible is already exhausted in a couple of months. For the remaining part of the
year, the patient only pays the co-insurance rate.
3 See the recent press release by the Swiss health insurance association (Sante´suisse, 2017) on the
international comparison between generic drug prices in Switzerland and prices in Belgium, Denmark,
Germany, Finland, France, Great Britain, the Netherlands, Austria, and Sweden.
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The prevalence rate of mental health problems in Switzerland is similar to other developed
countries (Schuler and Burla, 2012). Severe cases can be treated both in private and
public hospitals. Hospitals charge a daily fee which is decreasing with the length of
stay (Schneeberger and Schwartz, 2018). Cantons and health insurance provider share
the costs of psychiatric hospital stays. Although hospital admissions for mental health
disorders have increased over time, the number of psychiatric hospital beds per capita
has declined, and a growing number of patients is treated in outpatient settings. Similar
trends are observable for other European countries (Priebe et al., 2008). The fees for the
services provided by outpatient departments/clinics are standardized in the TARMED
tariff system to avoid differential treatment of patients with different insurance plans.
3. Data
We exploit two primary datasets on antidepressant sales and mental health outcomes
for Switzerland covering the period from 2002 to 2014. The data is aggregated at the
small area level (SMR - spatial mobility region) which divide Switzerland into 106 SMR
regions with each of them accounting for approximately 45,000 individuals. An SMR is a
statistical subdivision of Switzerland based on economic activity around an agglomeration
hub. As such, each region represents a local labor market or commuting zone.
The level of disaggregation allows us to account for population characteristics and neglect
possible consumption spillovers across regions. Indeed, people living in one region are
highly unlikely to work in a neighboring region and, therefore, to shop for antidepressants
outside the SMR of residence. Thus, measuring antidepressant consumption at the level of
commuting zones represents an effective way to deal with the potential for measurement
error. Nonetheless, an additional source of measurement error may arise from the use of
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wholesale data (from the manufacturer to the pharmacy/drugstore) since we measure what
the pharmacist stocks rather than sales to the final consumer. Although our observations
of final consumption are on average correct, we could overestimate antidepressant use in
some cases.
To account for confounding factors, we supplement our primary datasets on antidepressant
sales and mental health outcomes with data on essential covariates for each region and
year. These variables are the distribution of the population across gender and age, the
share of German-speaking people and the share of foreigners, and the average municipal
unemployment rate. Lastly, we obtained access to anonymized data by the Swiss Medical
Association (FMH), which allowed us to calculate the share of antidepressant prescribing
specialists (Neurologists and Psychiatrists) and GPs per 10,000 inhabitants.
3.1 Antidepressant sales and mental health outcomes
We obtained data on antidepressant sales from IMS Health Switzerland. This dataset
contains annual antidepressant sales at the product level by pharmaceutical sales region
(237 regions) from 2002 to 2014. This level of aggregation includes at least five pharmacies
to avoid identification of specific retailers. The level of detail allows us to calculate
the consumption of each antidepressant product in defined daily doses (DDD) per 1,000
inhabitants per year based on information from the WHO dataset on daily doses by
active ingredient. In particular, we consider sales data for the following Anatomical
Therapeutic Chemical classes (ATC): N06A4 (Selective Serotonin Reuptake Inhibitors -
SSRI), N06A5 (Serotonin and Norepinephrine Reuptake Inhibitors - SNRI), and N06A9
(Other antidepressants, including Tricyclic antidepressants - TCA) (see Table A.1 for
the active ingredients included in each classes). Although herbal medicines (class N06A2)
enjoy a high level of acceptance in the Swiss population, we exclude them from our analysis
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since we can not define the daily dose for this class of antidepressants. We also use an
accessory dataset with annual sales for the universe of all other drugs aggregated at the
manufacturer level by pharmaceutical sales region for the period from 2002 to 2014.4
We obtained individual-level data on mental health outcomes from the Federal Statistical
Office (FSO). The most detailed geographical aggregation at which hospital admission
data are available for Switzerland is the MedStat region level. The MedStat regions are a
geographical concept used by the FSO to anonymize individual-level hospital admission
data.5 We use a population-weighted matching procedure to reassign data aggregated at
the MedStat level to the SMR level, and from the pharmaceutical sales region to the SMR
level. The matching method allows us to build a final dataset with comparable spatial
data on both antidepressant consumption and mental health outcomes. We express mental
health outcomes in terms of annual prevalence per 10,000 inhabitants by SMR throughout
our analysis.
We consider three different mental health outcomes in our analysis. To capture the impact
on suicide, we create a measure of completed suicides and hospital admissions for suicide
attempts (Intentional Self-harm - X60-X84). We also account for hospital admissions
for depression (depressive episode - F32, and Recurrent Depressive Disorder - F33), and
hospitalizations for other mental health conditions (Chapter V).6 Data on mortality are
4 A negligible number of drugs with a retail price greater than 5, 000 CHF is also not included in the
analysis.
5 An advantage of these data is that the 604 MedStat regions are homogenous regarding the population
size, with each of them containing about 12,000 people. It is important to note that the spatial
definition was updated in 2008 to account for population growth. Based on postal codes for 2007,
the old MedStat regions were split up or combined to form new MedStat regions. Therefore, it is
impossible to study hospital admissions over the structural break without reassigning the data from
the new to the old definition of MedStat region. We accomplish this task by matching postal codes
underlying the MedStat regions over the structural break. We obtained detailed information on the
general population at the postal code level for 2010 from the FSO. We use this information to create
weights and recode the location information to obtain a match between the new and the old definition.
We then reassign the morbidity data over the structural break using population weights.
6 All disease codes refer to the International Statistical Classification of Diseases and Related Health
Problems, 10th Revision, of the WHO.
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from the official Swiss mortality statistics, and hospitalization data are from the Swiss
hospital statistics.
3.2 Descriptive evidence
We summarize the main variables used in our analysis in Table 1. The average antide-
pressant consumption across SMR regions and for the whole period under study is more
than 40 DDD per 1’000 inhabitants, with an increase of almost twenty DDD over the last
decade. The spatial and temporal variation in antidepressant consumption are illustrated
in Figure 1. We observe a sharp increase over time in all regions. However, most of the
variation is across small areas, and another important source of variation comes from the
introduction of new products. Figure 2 shows the number of newly introduced antide-
pressants per year.7 We will discuss the use of this source of variation to construct our
instrument for antidepressant consumption in Section 4. Interestingly, the consumption
is mostly concentrated in South-Western regions in 2003, while there is no clear concen-
tration in any region in 2014. Hence, the increase in consumption over time characterizes
a catching-up process with the strongest increase in the North-Eastern regions.
A similar pattern is observable for mental health outcomes in Figure 3. In particular,
hospital admissions for mental disorders and depression show a significant increase over
time. Subfigures (a) and (c) highlight the concentration of mental health disorders and
depression in South-Western regions in 2003. The prevalence of both mental disorders and
depression appear to increase in the North-Eastern areas compared to 2014 according to
subfigures (b) and (d). The variation in suicide rates provides a far more complex picture,
probably due to the rare-event nature of suicides. The comparison of subfigures (e) and
7 Additional details (manufacturer, active ingredient and year of introduction) for new brand name
products and generic drugs are provided respectively in Table A.2 and Table A.3.
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(f) does not seem to suggest a clear spatial or temporal pattern, although we see evidence
for an increasing number of cases in some Eastern regions.
4. Empirical strategy
Following previous literature on the effect of antidepressant sales or consumption on sui-
cides (e.g. Ludwig et al., 2009), our estimates of the effect of antidepressant sales on
mental health outcomes relies on the following empirical model:
yrt = α + βADrt + γXrt + ϑr + ϑt + rt, (1)
where yrt is the natural log of the mental health outcome (number of hospital admissions
for mental health problems, depression or number of suicides rates per 1’000 inhabitants
in year t)8 in region r at time t; ADrt represents antidepressants sales (expressed in
DDD per 1’000 inhabitants in year t) in the same region at the same time; Xrt is a
vector of controls, including demographics (the age distribution of the population, the
share of females, the share of German speakers, and the share of foreigners), the level of
unemployment in a region, and the density of antidepressant prescribing physicians; ϑr
are region fixed effects, ϑt are time fixed effects, and rt is an idiosyncratic error term. We
use the natural log of mental health outcomes to approximate a normal distribution for
our data, for ease of interpretation, and because of the convention in the literature.9 As
a robustness check, we also estimate (1) assuming a data generating process that mimics
the Poisson distribution.
We use the fixed effects (FE) estimator as our benchmark model to estimate Equation
8 Some concerns might arise having the population on both the left and right end side of our regression.
However, results are almost identical if we use the simple log count of our outcome variables.
9 We take care of zeros for suicides by adding a small constant to each outcome.
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(1). Given the substantial scale differences between small areas (we move from almost
half a million inhabitants in Zurich to less than 10,000 in Appenzell-Innerhoden), we
weight our estimates for the population. This weighting approach allows us to correct for
heteroskedasticity in the error term (Solon et al., 2015), and alleviate the measurement
error problem. Indeed, more populated areas show a higher signal-to-noise ratio, which
is an issue, especially when dealing with a low-frequency outcome such as suicides.10
Antidepressant consumption is endogenous to the conditions that also influence mental
health outcomes. The inclusion of region fixed effects allows us to remove all time-invariant
unobservables, but this does not allow us to get rid of all the endogeneity concerns. Several
omitted time-varying factors may still bias our estimates. The latent health status of
the population may affect both the use of antidepressants and the prevalence of mental
health disorders in a region causing an upward bias of our FE estimates. Moreover,
there have been attempts to create awareness of depression and decrease stigma in the
general population and among health care practitioners. We would expect such policy
interventions to have a positive effect on antidepressant sales since they encourage uptake
of antidepressant treatment, and possibly a negative impact on mental health outcomes.
Therefore, the bias in the estimates could be either upward or downward, depending on
which of the two effects is stronger.
Controlling for these factors is difficult because, for example, a reliable measure of depres-
sion prevalence is not available and we do not have enough power to measure the effect
of cantonal depression awareness campaigns.11 Moreover, the health status of the popu-
10 Comparing Zurich (a densely populated city) and Appenzell Innerhoden (a scarcely populated rural
area), we observe a large variability in the mental health outcomes (see Figure A.1).
11 The “Alliance against Depression” is active in several (German-speaking) Swiss cantons and creates
awareness for depression in the general population, and among physicians, teachers, etc. However, the
program’s scope, length and stakeholders are up to the discretion of the cantons.
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lation is an outcome as well (what Angrist and Pischke (2008) define as “bad controls”).
To account for this issue, we rely on an instrumental variables strategy to estimates the
impact of antidepressant sales on mental health outcomes.
4.1 Instrumental variable approach
The instrument for our identification strategy is an adaptation of the traditional shift-
share instrument (Bartik, 1991) where national levels of antidepressant sales for each
manufactures are assigned to regions using the supply-driven increase in antidepressant
sales. Our instrument diverges from the standard shift-share approach in two impor-
tant ways. First, we use regional market shares, rather than regional sales relative to
national sales, to calculate the regional shares. Indeed, the use of regional sales to calcu-
late the regional shares would be endogenous since most manufacturers are likely to sell
more in areas where the mental health conditions of the population are poor. The use
of market shares allows us to overcome this problem since we consider the sales of each
manufacturer relative to its competitors. Second, the market shares are computed using
non-antidepressant drugs sales. Therefore, we use a different market to exploit the market
power of each manufacturer in a region and to avoid concerns regarding the potential en-
dogeneity of our shares. We also normalize the final shares for each manufacturer against
the sum of its regional market shares (such that the share takes a value between zero and
one). Therefore, the weighted average of these shares and the national growth in annual
antidepressant sales per manufacturer (the shifts) is our instrument (Goldsmith-Pinkham
et al., 2018; Jaeger et al., 2018). In practice, we exploit the fact that manufacturers tend
to sell more in areas where they have higher market power (relative to their competitors).
Hence, we allocate the annual sales of antidepressant drugs of each manufacturer using
its regional market share for non-antidepressant drugs.
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To have predict power, we also need variation between manufacturers in their national
growth rate (net of the overall yearly change in AD sales captured by the time fixed
effects). As reported in Figure 2, the introduction of several new products in the market,
some covered by a new patent (brand name introduction), and some others as new generic
drugs (first or secondary introduction) provides this variation.
The underlying assumption of our IV strategy is that a manufacturer’s market share in
the non-antidepressant market is exogenous to mental health outcomes, and does not
affect the mental health outcomes of the population (exclusion restriction) directly. This
assumption is violated if pharmaceutical companies, through their market power in the
non-antidepressant market, were able to influence hospital admissions for severe mental
health problems, which is hard to believe.
Because of data restrictions, our main estimates are obtained using 2002 as a base year to
construct the shares, while analyzing the relationship between antidepressant sales and
mental health outcomes for data from 2003 to 2014. Although our shift shares are different
from those commonly employed in the literature, some concerns might still arise because
there is no time gap between the base year and the years for which we estimate the effect
of antidepressant sales on mental health outcomes. For this reason, we substantiate the
validity our instrument by re-estimating the model using increasing time gaps between
our base year (2002) and the years used for the estimation (using incrementally fewer
data in steps of one year).12 The robustness of our findings to the increasing time gap
confirms our main results.
More formally, our instrument is constructed as follows. Let the annual national stock of
12 A time gap of one year implies that we are using data from 2004 to 2014; a time gap of two years
implies that we are using data from 2005 to 2014, and so on.
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antidepressant for each manufacturer be represented by ADmt =
∑
r ADmrt, where ADmrt
represents the antidepressant sales for manufacturer m in region r at time t. The stock
is used to calculate the shifts. The shares instead are calculated as follows:
S˜mr2002 =
MSmr2002∑
rMSmr2002
, (2)
where MSmr2002 =
vmr2002∑
m vmr2002
is the market share from wholesales of non-antidepressants
(vmrt) for manufacturer m, in region r, in the base year 2002, with 0 < S˜mr,2002 < 1
13.
This allows us to redistribute ADmt as follows:
A˜Dmrt = S˜mrt × ADmt, (3)
where the regional variation in A˜Dmrt comes from variation in manufacturer non-antide-
pressant market shares in the base year, and temporal variation from national manufac-
turer growth rates. Finally, we sum A˜Dmrt over m to obtain our instrument as follows:
A˜Drt =
∑
m
A˜Dmrt. (4)
We can now exploit our instrument to estimate the model using a two-stage least squares
fixed-effects estimator (2SLS-FE). The first stage can then be written as
ADrt = α + τA˜Drt + ζXrt + ϑr + ϑt + rt. (5)
Since we interpret A˜Drt as the sales due to market power, we expect the sign of τ to
13 To construct these markets shares we use total sales based on ex-factory prices because we do not have
information on the single products and so on final prices.
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be positive if manufacturers actively push their sales in areas where they have a larger
market share.
It is worth reminding that the demand is not substantially driven by the patient who faces
virtually no costs, and antidepressants are exclusively prescribed by physicians. Moreover,
prices are set at the federal level, so manufacturers can only compete on quantity by
physician detailing. As such, our instrument captures the potential influence that a
manufacturer can exert in a certain area with respect to its competitors in that area. τ
captures how much this market power actually influences antidepressant sales.
The estimate obtained from the first stage is then used in the second stage as
yrt = α + βÂDrt + γXrt + ϑr + ϑt + rt, (6)
where ÂDrt is the predicted antidepressant consumption obtained from (5). β can then be
interpreted as the effect of a change in the exogenous share of antidepressant consumption
on mental health outcomes and, therefore, as the causal effect of antidepressant consump-
tion on mental health outcomes. One should bear in mind that we do not estimate the
average treatment effect, but instead the local average treatment effect (LATE) (Angrist
et al., 1996). In particular, we measure the effect of antidepressant consumption on men-
tal health outcomes for those who consumed antidepressants because of the manufacturer
market power but would not have used antidepressant had market power been absent.
Given the count nature of our original outcomes (before the log transformation), we
evaluate the robustness of our results to the use of non-linear estimation methods bases
on a Poisson count data model. Following Terza et al. (2008), we take the endogeneity
of antidepressant sales into account in a non-linear model using the so-called “two-stage
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residual inclusion”, which is a two-step procedure similar to the control function approach
where the residuals from the first stage are included in the main regression equation.
5. Results
Table 2 shows the baseline results for our analysis. For each mental health outcome (hos-
pital admissions for mental disorders, hospital admissions for depression, and suicides), we
present the results of two model specifications. Model (1) includes demographic controls
and year and region fixed effects. This model is our preferred specification because it in-
cludes only regional demographic characteristics, which should not be affected by changes
in AD consumption. Model (2) includes physician density and unemployment rate as
additional regressors, which might be affected by changes in antidepressant consumption
(potentially biasing our estimates). Reported standard errors are robust and clustered at
the small area level, and all reported statistics are also corrected for small sample size.
As the benchmark, we report the results obtained from OLS estimations on the within
transformation (fixed effects) in the first row of Table 2. The OLS estimates indicate
that a one DDD increase in antidepressant sales in a region is associated with 1.3% more
hospital admissions for depression, while there is no evidence of a significant correlation
with hospitalizations for mental disorders in general. The estimates of antidepressant
sales on suicides are also statistically insignificant.
The second row of Table 2 reports the results of our 2SLS estimates, while we provide the
respective first stage and reduced form results in the third and fourth rows. Even when
we exploit the arguably exogenous variation in antidepressant sales due to differences in
market shares of pharmaceutical companies’, we find that an increase in antidepressant
sales substantially increases hospital admissions for mental disorder and depression. The
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estimated effects are also larger in magnitude than those estimated with OLS. In particu-
lar, we find that a one unit increase in DDD of antidepressant sales per 1’000 inhabitants
leads to a change of hospital admission for mental health disorders of 2.2%. This effect
that is mainly driven by the increase in hospitalization for depression (+ 7%).14 As for
the estimated effect of antidepressant sales on suicides, we find no evidence for a positive
relationship and the point estimates suggest a slightly negative impact (less than half
percentage point).
We report the first-stage results in the third row of Table 2. The estimates show that
our instrument predicts antidepressant sales well. Although the value of the Kleijbergen-
Paap F-statistic for weak instruments is only slightly above ten for model specification
(2), it is worth noting that we have saturated the model with a full set of control vari-
ables and fixed effects, and reported the most restrictive standard errors accounting for
small-sample statistics. Therefore, the results represent conservative estimates of the re-
lationship between antidepressant sales and mental health outcomes. Reassuringly, the
fourth row of Table 2 also provides evidence for the presence of significant reduced form
effects, especially for hospital admissions related to depression.
Table A.4 presents estimation results for exploiting heterogeneity by gender and age
groups. Our findings do not show evidence of considerable heterogeneity, except for a
somewhat lower effect (4.0% vs. an average of 7.5%) on hospital admissions for depres-
sion for the elderly (43.0% in the age 65+ vs. 7.7% in the age 20-65). It is worth noting
that while our outcomes vary by gender and age, antidepressant sales and the instrument
do not.
14 The estimates of the impact on all mental disorders excluding depression are smaller and not statisti-
cally significant.
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5.1 Robustness checks
We use 2002 as the base year in our baseline regression model and estimate the treatment
effect for the period from 2003 to 2014. As a robustness check, we keep the base year at
2002 and, in steps of one year, we use incrementally fewer data to estimate the treatment
effects. In practice, we increase the time gap between the base year used to construct
the share and our observation window. By doing so, we effectively decrease the sample
size and, therefore, the variation that we can exploit. Nonetheless, we find for all three
outcomes consistent point estimates and standard errors (Figure 4). Subfigure (a) shows
an increase in the treatment effect for mental health disorders using more recent data.
Moreover, the estimates for depression appear to become more precise with a decreasing
sample size as indicated in Subfigure (b) of Figure 4. These findings reassure us that our
instrument does indeed address the endogeneity concerns.
We report 2SLS estimates of the effect of an increase in antidepressant sales on a set of
placebo outcomes in Table A.5. Specifically, we choose five causes of hospitalization that
should not be affected by an increase in antidepressant sales. These causes are neoplasm
(cancer), infectious diseases, bone fractures, pregnancy and diseases of the lens. They
are selected to match the mean and standard deviation of our primary outcomes. Except
for cancer, none of the outcomes shows any significant correlation with the instrumented
antidepressant sales. In the case of cancer, however, the correlation is negative, which
suggests a bias in the opposite direction. In the case of instrument endogeneity, we
could expect a positive relationship between antidepressant use and hospital admissions
for cancer because patients with cancer also receive antidepressant to deal with pain
and related depression. More likely, the negative correlation is driven by the fact that
the shares of our shift-share instrument are constructed using non-antidepressant drug
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sales, and cancer drugs represent a significant component of these sales (because they are
particularly expensive). Ideally, one would construct the baseline shares of our instrument
by removing cancer drugs from the baseline market shares but, unfortunately, we do not
have access to such disaggregated data for cancer at the product level. Reassuringly, as we
increase the time gap between the base year used to construct the share, the correlation
between our instrument and hospital admissions for cancer fade away (see Figure A.2).
Table A.6 shows that the 2SLS results are qualitatively similar when we take into account
the count nature of the outcome variables. We apply an IV strategy to Poisson models
using the control function approach. The point estimates with this method are even larger
than those reported using the log-linear regression model.15
6. Conclusion
This research sheds light on the mental health effects of the dramatic increase in antide-
pressant consumption observed in Switzerland in the last two decades – a phenomenon
that is also present in many other developed countries. Our contribution to this debate
consists of quantifying the relationship between antidepressant sales and mental health
outcomes employing an instrumental variable strategy. Using plausibly exogenous varia-
tion in local market shares of pharmaceutical companies and product innovation, we find
that antidepressant sales increase hospital admissions for mental disorder by 2.2% and by
7.2% for depression, respectively. Conversely, our estimation results show no evidence for
a significant effect on suicides. The results for mental health disorders are mainly driven
by depression and should be interpreted with caution. In particular, as it is often the case
in IV settings, our estimates allow recovering only the effect for the subpopulation of com-
15 The difference arises mainly because of different weighting approaches in the two statistical models.
Indeed, we cannot use population weights in the Poisson model and this affects the size of the first
stage coefficient (0.295 versus 0.451).
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pliers (LATE), which may not coincide with the average effect for the whole population
(ATE).
The fact that we do not find any significant effect of antidepressant sales on suicides is
worth discussing, particularly because Ludwig et al. (2009) find that the increase in SSRI
use decreases suicide mortality by 5%. These authors compare SSRI use across countries
and over time in the 80s and the 90s. At that time, SSRI were promoted as being more
efficient than TCA, particularly in terms of reduced side effects. Because the analysis
includes the introduction period of SSRI, the study probably captures the initial impact
of their uptake. The current market, however, is dominated by drugs in the SSRI class.
Or results should be considered in light of the current levels of treatment with antidepres-
sants. Evidence suggests that the prescription threshold for antidepressants has shifted
towards the lower end of the severity distribution of depression, despite prescription guide-
lines dictate psychotherapy for mild depression and, at most, a combination of psychother-
apy and pharmacotherapy for moderate cases. Our estimation results also indicate that
people are hospitalized for depression in areas with higher antidepressant sales. These re-
sults could imply that the marginal patient treated with antidepressants nowadays may no
longer benefit from antidepressant treatment, although our estimates indicate the LATE
rather than the population-averaged effect. In particular, we measure the impact for those
who are induced to consume antidepressants as a result of market power exerted by phar-
maceutical companies, and would not have consumed antidepressants otherwise. A policy
recommendation would be, therefore, to put measures in place to ensure adherence to the
prescription guidelines and emphasize the importance of alternatives to pharmacotherapy.
Our research does not shed light on the cause of over-treatment with pharmacotherapy.
Over-treatment could, for example, be the result of undercapacity of psychotherapists.
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Psychotherapy is more a time-consuming form of treatment than prescribing antidepres-
sants. Decreasing stigma and increased awareness may have led the number of patients
to grow to such an extent that physicians have resorted to pharmacotherapy, even if this
therapy is not the best treatment option.
23
References
Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K.,
McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008). Evidence-based guide-
lines for treating depressive disorders with antidepressants: A revision of the 2000
British Association for Psychopharmacology guidelines. Journal of Psychopharmacol-
ogy, 22(4):343–396.
Anderson, I. M., Nutt, D. J., and Deakin, J. (2000). Evidence-based guidelines for treating
depressive disorders with antidepressants: A revision of the 1993 British Association
for Psychopharmacology guidelines. Journal of Psychopharmacology, 14(1):3–20.
Angrist, J. D., Imbens, G. W., and Rubin, D. B. (1996). Identification of causal ef-
fects using instrumental variables. Journal of the American Statistical Association,
91(434):444–455.
Angrist, J. D. and Pischke, J.-S. (2008). Mostly harmless econometrics: An empiricist’s
companion. Princeton University Press.
Bartik, T. J. (1991). Who benefits from state and local economic development policies?
Technical report, Upjohn Institute for Employment Research.
Biller-Andorno, N. and Zeltner, T. (2015). Individual responsibility and community soli-
darity – The Swiss health care system. New England Journal of Medicine, 373(23):2193–
2197.
Busch, S. H., Golberstein, E., and Meara, E. (2014). The FDA and ABCs Unintended
Consequences of Antidepressant Warnings on Human Capital. Journal of Human Re-
sources, 49(3):540–571.
Cipriani, A., Zhou, X., Del Giovane, C., Hetrick, S. E., Qin, B., Whittington, C., Coghill,
D., Zhang, Y., Hazell, P., Leucht, S., et al. (2016). Comparative efficacy and tolerability
of antidepressants for major depressive disorder in children and adolescents: A network
meta-analysis. Lancet, 388(10047):881–890.
24
Cleare, A., Pariante, C. M., Young, A. H., Anderson, I. M., Christmas, D., Cowen,
P. J., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015). Evidence-based
guidelines for treating depressive disorders with antidepressants: A revision of the 2008
British Association for Psychopharmacology guidelines. Journal of Psychopharmacol-
ogy, 29(5):459–525.
Cohen, H. W., Gibson, G., and Alderman, M. H. (2000). Excess risk of myocardial
infarction in patients treated with antidepressant medications: Association with use of
tricyclic agents. American Journal of Medicine, 108(1):2–8.
Coupland, C., Dhiman, P., Morriss, R., Arthur, A., Barton, G., and Hippisley-Cox, J.
(2011). Antidepressant use and risk of adverse outcomes in older people: Population
based cohort study. BMJ, 343:d4551.
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton,
R. C., and Fawcett, J. (2010). Antidepressant drug effects and depression severity: A
patient-level meta-analysis. Journal of the American Medical Association, 303(1):47–53.
Gibbons, R. D., Hur, K., Bhaumik, D. K., and Mann, J. J. (2005). The relationship
between antidepressant medication use and rate of suicide. Archives of General Psy-
chiatry, 62(2):165–172.
Goldsmith-Pinkham, P., Sorkin, I., and Swift, H. (2018). Bartik instruments: What,
when, why, and how. Technical Report 24408, National Bureau of Economic Research.
Hammad, T. A., Laughren, T., and Racoosin, J. (2006). Suicidality in pediatric patients
treated with antidepressant drugs. Archives of General Psychiatry, 63(3):332–339.
Healy, D. and Whitaker, C. (2003). Antidepressants and suicide: Risk-benefit conun-
drums. Journal of Psychiatry and Neuroscience, 28(5):331.
Jaeger, D. A., Ruist, J., and Stuhler, J. (2018). Shift-share instruments and the impact
of immigration. Technical Report 24285, National Bureau of Economic Research.
25
Jakobsen, J. C., Katakam, K. K., Schou, A., Hellmuth, S. G., Stallknecht, S. E., Leth-
Møller, K., Iversen, M., Banke, M. B., Petersen, I. J., Klingenberg, S. L., et al. (2017).
Selective serotonin reuptake inhibitors versus placebo in patients with major depressive
disorder. A systematic review with meta-analysis and trial sequential analysis. BMC
Psychiatry, 17(1):58.
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., and Johnson,
B. T. (2008). Initial severity and antidepressant benefits: A meta-analysis of data
submitted to the Food and Drug Administration. PLOS Medicine, 5(2):e45.
Lane, R., Baldwin, D., and Preskorn, S. (1995). The SSRIs: Advantages, disadvantages
and differences. Journal of Psychopharmacology, 9(2):163–178.
Ludwig, J., Marcotte, D. E., and Norberg, K. (2009). Anti-depressants and suicide.
Journal of Health Economics, 28(3):659–676.
Masiero, G., Mazzonna, F., and Verbeek, O. (2018). What drives the rise of antidepressant
consumption? Evidence from Switzerland. Technical report, IdEP Economic Papers,
Universita` della Svizzera italiana.
McCarthy, M. (2013). Antidepressant use has doubled in rich nations in past 10 years.
BMJ, 347:f7261.
Moore, M., Yuen, H. M., Dunn, N., Mullee, M. A., Maskell, J., and Kendrick, T. (2009).
Explaining the rise in antidepressant prescribing: A descriptive study using the general
practice research database. BMJ, 339:b3999.
Pratt, L., Brody, D., and Gu, Q. (2011). Antidepressant use in persons aged 12 and over:
United States, 2005-2008. Technical report, NCHS Data Brief.
Priebe, S., Frottier, P., Gaddini, A., Kilian, R., Lauber, C., Mart´ınez-Leal, R., Munk-
Jørgensen, P., Walsh, D., Wiersma, D., and Wright, D. (2008). Mental health care
institutions in nine European countries, 2002 to 2006. Psychiatric Services, 59(5):570–
573.
26
Sante´suisse (2017). Press release, 4 June 2017. https://www.santesuisse.ch/fileadmin/-
sas content/Comm 2017-04-06-d.pdf.
Schneeberger, A. R. and Schwartz, B. J. (2018). The Swiss Mental Health Care System.
Psychiatric Services, 69(2):126–128.
Schuler, D. and Burla, L. (2012). Psychische Gesundheit in der Schweiz: Monitoring
2012. Schweizerisches Gesundheitsobservatorium (Obsan).
Sharma, T., Guski, L. S., Freund, N., and Gøtzsche, P. C. (2016). Suicidality and aggres-
sion during antidepressant treatment: Systematic review and meta-analyses based on
clinical study reports. BMJ, 352:i65.
Solon, G., Haider, S. J., and Wooldridge, J. M. (2015). What are we weighting for?
Journal of Human Resources, 50(2):301–316.
Stone, M., Laughren, T., Jones, M. L., Levenson, M., Holland, P. C., Hughes, A., Ham-
mad, T. A., Temple, R., and Rochester, G. (2009). Risk of suicidality in clinical trials
of antidepressants in adults: Analysis of proprietary data submitted to US Food and
Drug Administration. BMJ, 339:b2880.
Terza, J. V., Basu, A., and Rathouz, P. J. (2008). Two-stage residual inclusion estimation:
Addressing endogeneity in health econometric modeling. Journal of Health Economics,
27(3):531–543.
27
 (0҆20)  (20҆40)  (40҆60)  (60҆80)  (80҆100)
(a) Antidepressant sales in 2003
 (0҆20)  (20҆40)  (40҆60)  (60҆80)  (80҆100)
(b) Antidepressant sales in 2014
Figure 1: Antidepressant sales in Switzerland by small areas in 2003 and 2014
Notes – The figure examines antidepressant sales in Switzerland at the small area level for 2003 and
2014. To compare drug sales across regions, we classify the annual consumption according to five classes
ranging from low to high where darker shades stand for higher consumption levels.
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Figure 2: Introduction of new anti-depression drugs in Switzerland from 2002 to 2014
Notes – The figure shows the introduction of new antidepression drugs in Switzerland from 2002 to 2014.
Light red bars indicate brand name products, red bars primary generic products, and dark red bars
secondary generic products, respectively.
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Figure 3: Mental health outcomes in Switzerland by small areas in 2003 and 2014
Notes – The figure classifies the prevalence of mental health disorder, depression, and suicide for 2003
and 2014. The health outcomes are categorized according to five classes ranging from low to high where
darker shades stand for higher incidences.
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Figure 4: Parameter estimates by health outcome relative to 2002
Notes – The figure shows IV estimates for mental disorder (a), depression (b),
and suicide (c) increasing the time gaps used for the estimation relative to
the base year 2002. We report the parameter estimates and the corresponding
95% confidence intervals.
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Table 1: Descriptive statistics
Standard deviation
Mean Overall Between Within ∆(2003/14) Min Max
Antidepressant use 42.57 13.13 11.07 7.14 17.61 15.16 96.13
Mental disorder 94.23 26.43 22.73 13.65 16.54 22.16 219.08
Depression 20.54 7.32 5.02 5.35 6.12 2.89 56.07
Suicide 1.40 0.71 0.30 0.65 -0.19 0.00 6.68
Unemployment rate 2.63 1.16 1.07 0.47 -0.23 0.51 6.86
Below age 15 share 15.84 1.83 1.56 0.97 -2.32 10.03 21.29
Between age 15-65 share 67.22 1.77 1.68 0.56 -0.11 60.34 71.58
Over age 65 share 16.93 2.43 2.26 0.90 2.43 10.52 24.56
Female share 50.48 0.85 0.81 0.26 -0.50 47.92 52.94
Foreigner share 18.56 7.16 7.03 1.49 3.69 3.65 40.95
German-speaking share 64.30 37.25 37.42 0.01 -0.00 1.58 96.77
Specialists 2.30 2.34 2.28 0.59 1.08 0.00 14.98
General practitioners 6.65 1.52 1.38 0.66 0.22 2.63 11.99
Notes – The table reports the descriptive statistics for the main variables. The statistics are obtained
using annual data at the small area level for the period from 2003 to 2014. Antidepressant use is measured
in terms of defined daily doses per 1,000 inhabitants and day, Mental disorder and depression are expressed
in terms of hospital admissions. Specialists and general practitioners are measured by the density per
10,000 population.
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Table 2: Estimates of the effect of antidepressant sales on mental health outcomes
Outcomes (ln): Mental disorder Depression Suicide
Model (1) (2) (1) (2) (1) (2)
OLS 0.004 0.004 0.013*** 0.013** 0.001 0.000
(0.003) (0.003) (0.005) (0.005) (0.003) (0.003)
2SLS 0.022** 0.022** 0.076*** 0.072*** -0.004 -0.005
(0.010) (0.010) (0.027) (0.025) (0.010) (0.011)
1st stage 0.451*** 0.427*** 0.451*** 0.427*** 0.451*** 0.427***
(0.130) (0.135) (0.130) (0.135) (0.130) (0.135)
Reduced form 0.010** 0.009** 0.034*** 0.031*** -0.002 -0.002
(0.004) (0.004) (0.006) (0.005) (0.005) (0.005)
Year FE Yes Yes Yes Yes Yes Yes
Region FE Yes Yes Yes Yes Yes Yes
Demographics Yes Yes Yes Yes Yes Yes
Physician density No Yes No Yes No Yes
Unemployment rate No Yes No Yes No Yes
Observations 1,272 1,272 1,272 1,272 1,272 1,272
Kleijbergen-Paap F 11.99 10.03 11.99 10.03 11.99 10.03
Notes – The table reports the parameter estimates for each health outcome (mental disorder, depression, and
suicide) for the linear regression model and the instrumental variable regression model. We control for year
and region fixed effects and population characteristics in the specification (1) and include additional control
variables in the specification (2). We use cluster-robust standard errors at the small area level and report
small sample statistics. Significance levels at 10%, 5%, and 1% indicated by ∗, ∗∗, and ∗∗∗, respectively.
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Figure A.1: Variability of mental health outcomes for Zurich and Appenzell Innerrhoden
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Figure A.2: Parameter estimates for placebo outcome relative to 2002
Notes – The figure shows IV estimates for cancer relative to the base year 2002. We report the parameter
estimates and the corresponding 95% confidence intervals.
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Table A.1: Antidepressant molecules
ATC class Molecules
N06A4 Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Ser-
traline
N06A5 Duloxetine, Venlafaxine
N06A9 Agomelatine, Amitriptyline, Bupropion, Clomipramine, Dibenzepin,
Dosulepin, Doxepin, Imipramine, Lofepramine, Maprotiline, Mi-
anserin, Mirtazapine, Moclobemide, Nefazodone, Nortriptyline,
Opipramol, Reboxetine, Trazodone, Trimipramine
Notes – The table reports the antidepressant molecules included in the analysis. The ATC classes
N06A4 (Selective serotonin re-uptake inhibitors - SSRI) and N06A5 (Serotonin norepinephrine
re-uptake inhibitors - SNRI) represent recent drug classes and N06A9 (tricyclic antidepressants
and others) older drug classes. We excluded the class N06A2 (herbal antidepressants) because
defined daily doses cannot be calculated for herbal medicine.
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Table A.2: Introduction of brand name antidepressants
Pharmaceutical company Active ingredient Year
Lundbeck Escitalopram 2002
Eli Lilly Duloxetine 2006
GSK Pharma Bupropion 2007
Servier Agomelatine 2010
Notes – The table reports the introduction of new brand name antidepressants by
manufacturer and year. We do not include the introduction of a new mode of drug
administration or package size.
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Table A.3: Introduction of generic antidepressants
Pharmaceutical company Active ingredient Year
Sandoz Citalopram 2002
Sandoz Moclobemide 2002
Mepha-Teva Mianserin 2004
Mepha-Teva Paroxetine 2004
Sandoz Fluvoxamine 2004
Sandoz Trimipramine 2004
Spirig Healthcare Paroxetine 2004
Acino Pharma Fluoxetine 2004
Helvepharm Citalopram 2004
Mepha-Teva Citalopram 2004
Sandoz Citalopram 2004
Spirig Healthcare Citalopram 2004
Streuli Pharma Citalopram 2004
Helvepharm Sertraline 2005
Mepha-Teva Sertraline 2005
Sandoz Sertraline 2005
Spirig Healthcare Sertraline 2005
Streuli Pharma Sertraline 2005
Helvepharm Paroxetine 2005
Mepha-Teva Paroxetine 2005
Sandoz Fluoxetine 2005
Sandoz Paroxetine 2005
Streuli Pharma Fluoxetine 2005
Streuli Pharma Paroxetine 2005
Winthrop Citalopram 2005
Mepha-Teva Fluoxetine 2006
Sandoz Sertraline 2006
Acino Pharma Fluoxetine 2007
Actavis Sertraline 2007
Helvepharm Fluoxetine 2007
Mepha-Teva Fluoxetine 2007
Sandoz Sertraline 2007
Mepha-Teva Venlafaxine 2008
Sandoz Venlafaxine 2008
Actavis Citalopram 2008
Adico Pharma Fluoxetine 2008
Mepha-Teva Citalopram 2008
continues on next page
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Table A.3 – Continued from previous page
Pharmaceutical company Active ingredient Year
Mepha-Teva Fluoxetine 2008
Mepha-Teva Sertraline 2008
Semo Trading Citalopram 2008
Semo Trading Sertraline 2008
1a Pharma Citalopram 2009
1a Pharma Paroxetine 2009
1a Pharma Sertraline 2009
Actavis Fluoxetine 2009
Actavis Paroxetine 2009
Actavis Sertraline 2009
Actavis Venlafaxine 2009
Axapharm Fluoxetine 2009
Drossapharm Venlafaxine 2009
Helvepharm Venlafaxine 2009
Mepha-Teva Sertraline 2009
Sandoz Venlafaxine 2009
Actavis Sertraline 2010
Helvepharm Venlafaxine 2010
Mepha-Teva Venlafaxine 2010
Pfizer Sertraline 2010
Sandoz Trimipramine 2010
Sandoz Venlafaxine 2010
Spirig Healthcare Fluoxetine 2010
Spirig Healthcare Venlafaxine 2010
Helvepharm Mirtazapine 2011
Mepha-Teva Mirtazapine 2011
Sandoz Mirtazapine 2011
Streuli Pharma Mirtazapine 2011
Helvepharm Citalopram 2011
Pfizer Citalopram 2011
Pfizer Sertraline 2011
Pfizer Venlafaxine 2011
Sandoz Trimipramine 2011
Sanofi-Aventis Trimipramine 2011
Actavis Mirtazapine 2012
Mepha-Teva Venlafaxine 2012
Pfizer Citalopram 2012
continues on next page
39
Table A.3 – Continued from previous page
Pharmaceutical company Active ingredient Year
Sandoz Mirtazapine 2012
Spirig Healthcare Mirtazapine 2012
Actavis Citalopram 2013
Actavis Fluoxetine 2013
Actavis Escitalopram 2014
Axapharm Escitalopram 2014
Helvepharm Escitalopram 2014
Mepha-Teva Escitalopram 2014
Sandoz Escitalopram 2014
Spirig Healthcare Escitalopram 2014
Actavis Citalopram 2014
Actavis Venlafaxine 2014
Notes – The table reports the introduction of generic antidepressants by manufacturer
and year. First introducers are highlighted in italic. We do not include the introduction
of a new mode of drug administration or a different package size.
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Table A.4: Estimates of the effect of antidepressant sales on mental health outcomes by sex
and age groups
Outcomes (ln): Mental disorder Depression Suicide
Model (1) (2) (1) (2) (1) (2)
Males
2SLS 0.018 0.018 0.074** 0.067** -0.012 -0.013
(0.011) (0.011) (0.031) (0.028) (0.013) (0.014)
Females
2SLS 0.026** 0.025*** 0.076*** 0.073*** 0.020 0.022
(0.010) (0.009) (0.025) (0.023) (0.016) (0.017)
Age < 20
2SLS 0.011 0.008 0.076*** 0.079*** 0.004 0.002
(0.012) (0.010) (0.026) (0.027) (0.016) (0.018)
Age 20− 65
2SLS 0.025** 0.025** 0.082** 0.077*** 0.002 0.001
(0.012) (0.012) (0.032) (0.029) (0.011) (0.011)
Age > 65
2SLS 0.019* 0.019* 0.046*** 0.043*** -0.036 -0.040
(0.010) (0.010) (0.016) (0.015) (0.022) (0.025)
Year FE Yes Yes Yes Yes Yes Yes
Region FE Yes Yes Yes Yes Yes Yes
Demographics Yes Yes Yes Yes Yes Yes
Physician density No Yes No Yes No Yes
Unemployment rate No Yes No Yes No Yes
Observations 1,272 1,272 1,272 1,272 1,272 1,272
Kleijbergen-Paap F 11.99 10.03 11.99 10.03 11.99 10.03
Notes – The table reports the second stage IV estimates for each health outcome (mental disorder, depression,
and suicide) separated by gender and age. We control for year and region fixed effects and population
characteristics in the specification (1) and include additional control variables in the specification (2). We
use cluster-robust standard errors at the small area level and report small sample statistics. Significance
levels at 10%, 5%, and 1% indicated by ∗, ∗∗, and ∗∗∗, respectively.
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Table A.5: Placebo estimates using alternative hospitalization outcomes
Outcomes (ln):
Neoplasms Infectious
diseases
Bone
fractures
Pregnancy
and
childbirth
Diseases
of the lens
2SLS -0.011** 0.001 0.003 0.010 0.072*
(0.005) (0.007) (0.009) (0.007) (0.043)
Year FE Yes Yes Yes Yes Yes
Region FE Yes Yes Yes Yes Yes
Demographics Yes Yes Yes Yes Yes
Observations 1,272 1,272 1,272 1,272 1,272
Kleijbergen-Paap F 11.99 11.99 11.99 11.99 11.99
Mean 116.03 35.55 150.97 111.36 7.72
Within SD 16.11 9.41 23.34 11.28 8.02
Between SD 15.15 6.97 27.91 13.07 5.12
Notes – The table reports the second-stage IV estimates for the placebo outcomes. We control for year and
region fixed effects and population characteristics in the regression models. The placebo outcomes (ICD10
codes) are neoplasms (C00-C97 & D00-D09 & D10-D36 & D37-D48), certain infectious and parasitic
diseases (A-B), bone fractures (S), sexually transmitted diseases (A50-A64), and pregnancy, childbirth
and the puerperium (O). We use cluster-robust standard errors at the small area level. Significance at
10%, 5%, and 1% indicated by ∗, ∗∗, and ∗∗∗, respectively.
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Table A.6: Poisson estimates of the effect of antidepressant sales on mental health outcomes
Outcomes: Mental disorder Depression Suicide
Model (1) (2) (1) (2) (1) (2)
Poisson 0.001 0.001 0.012** 0.009** 0.007 0.005
(0.002) (0.002) (0.005) (0.004) (0.006) (0.005)
Poisson 2SLS 0.030** 0.033** 0.119*** 0.123*** 0.005 -0.005
(0.013) (0.015) (0.023) (0.026) (0.030) (0.037)
Residuals -0.030** -0.033** -0.114*** -0.119*** -0.001 0.008
(0.013) (0.016) (0.024) (0.026) (0.029) (0.037)
1st stage 0.295*** 0.252*** 0.295*** 0.252*** 0.295*** 0.252***
(0.077) (0.077) (0.077) (0.077) (0.077) (0.077)
Year FE Yes Yes Yes Yes Yes Yes
Region FE Yes Yes Yes Yes Yes Yes
Demographics Yes Yes Yes Yes Yes Yes
Physician density No Yes No Yes No Yes
Unemployment rate No Yes No Yes No Yes
Observations 1,272 1,272 1,272 1,272 1,272 1,272
Kleijbergen-Paap F 11.99 10.03 11.99 10.03 11.99 10.03
Notes – The table reports the parameter estimates for each mental health outcome (mental disorder, de-
pression, and suicide) for the Poisson model and the Poisson instrumental variable regression model. We
control for year and region fixed effects and population characteristics in the specification (1) and include
additional control variables in the specification (2). We use cluster-robust standard errors at the small area
level. Significance levels at 10%, 5%, and 1% indicated by ∗, ∗∗, and ∗∗∗, respectively.
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